Potential Effect Of Curcumin Research Articles

Potential Effect of Curcumin in Lowering Blood Glucose Level in Streptozotocin-Induced Diabetic Rats.

The prevalence of diabetes mellitus has significantly increased, with 537 million individuals living with diabetes in 2021. Curcumin, a natural compound present in turmeric, has anti-inflammatory and antioxidant properties that aid in controlling diabetes. Curcumin can lower blood glucose levels, increase pancreatic cell function, and reduce insulin resistance. The pathophysiology of diabetes involves oxidative stress and endoplasmic reticulum stress, which can lead to cell death. This study aimed to evaluate the antidiabetic activity of curcumin in rats by administering it for a month and evaluating pancreatic tissue histology. STZ-induced diabetic rats were fed a high-fat diet containing glibenclamide, 200 mg/kg body weight (BW) curcumin, 400 mg/kg BW curcumin, or a placebo for 4 weeks. After intervention, blood glucose levels were measured, and the pancreatic tissue was examined. Blood glucose levels were measured at 0, 2, 4, 6, and 8 h. One-way ANOVA was performed to measure the mean difference among the groups at 0, 2, 4, 6, and 8 h of observation, which reported a statistically significant difference (p < 0.05). The blood glucose levels decreased after 4 h in the group receiving curcumin. Histological evaluation of the pancreas showed slight hydropic degeneration after 4 weeks of curcumin treatment. Our study indicates that curcumin has a beneficial effect in diabetic rats by reducing blood glucose levels and a protective effect on the pancreas.

The Effectiveness of Turmeric (Curcuma domestica) in Decreasing The Risk of Atherosclerosis

Every year more than 36 million people die due to Non-Communicable Diseases (NCD). Globally, the number one cause of death for NCD every year is cardiovascular disease. Coronary heart disease, heart failure, hypertension and stroke are cardiovascular diseases. Atherosclerosis can be a cause of cardiovascular disease. One of the therapies that can be done to treat atherosclerosis is curcumin compound. Curcumin is an active compound in turmeric (Curcuma domestica) which functions in reducing cholesterol, antioxidant, antitoxin and anti-inflammatory. Therefore, the potential effect of curcumin can be an alternative therapy to reduce the risk of atherosclerosis. This study aims to prove the effectiveness of turmeric as an alternative therapy in reducing the risk of atherosclerosis. This type of research is a descriptive form of literature study that is made using secondary data in the form of sources obtained from library studies. The method used is collecting research results from various journals, case reports and research articles. From several studies conducted on humans, curcumin is safe to use and does not show toxic effects up to a dose of 500 mg given 2 times a day for 30 days. Curcuminoids found in turmeric have benefits as anti-inflammatory and antioxidant so that they can be used as alternative therapies for atherosclerosis.

Lipid lowering potential and potentiation effect of curcumin and atorvastatin in-patient with hyperlipidemia

Hyperlipidemiais a term that refers to any of several acquired or genetic disorders that result in a high level of circulating lipids (fats, cholesterol and triglycerides). The condition can affect one fat protein or several. Most people will have no symptoms, with increasing the risk of developing heart problem. It has been found that oxidation processes play important role in developing lipids disorders. Curcumin is a phytochemical antioxidant substance may play a role in lowering lipids levels in the blood.This study was conducted to evaluate the lipid lowering effect of curcumin in Iraqi patients with hyperlipidemia and to study the potentiation effect on atorvastatin.From thosepatients who attendedMedical Clinic in Al-Diwanyiah Teaching Hospital,48 patients of 45-65 years old with diagnosed hyperlipidemia were enrolled in this study,they were divided randomlyinto four groups,12 patients in each. Base line assessment was done in form oflipid profile. 1stgroup was considered as placebo,2ndgroups received atorvastatin,3rd group received curcumin and 4th group received atorvastatin + curcumin. Reassessment was done after 2 months.Curcumin group shows significant reduction in TG (P ≤ o.o5), significant reduction of LDL in atorvastatin group (P≤ 0.05) and highly significant reduction in LDL,TG,and significant reduction in TC in patients received both atorvastatin + curcumin,with no significanteffects on HDL in all treated groups,compared to placebo.curcumin express lipid lowering activity and potentiate atorvastatin action in patient with hyperlipidemia.

Curcumin potentiates the effect of chemotherapy against acute lymphoblastic leukemia cells via downregulation of NF-κB.

Acute lymphoblastic leukemia (ALL) accounts for 30% of all pediatric cancers. Currently available treatments exhibit toxicity and certain patients may develop resistance. Thus, less toxic and chemoresistance-reversal agents are required. In the present study, the potential effect of curcumin, a component of Curcuma longa, as a pharmacological co-adjuvant of several chemotherapeutic agents against ALL, including prednisone, 6-mercaptopurine, dexamethasone, cyclophosphamide, l-asparaginase, vincristine, daunorubicin, doxorubicin, methotrexate and cytarabine, was investigated in the REH ALL cell line cultures treated in combination with chemotherapeutic agents and curcumin. The results of cell viability, gene expression and activation of NF-κB and caspase 3 indicated that curcumin potentiates the anticancer effects of the aforementioned chemotherapeutic agents in the REH ALL cell line. Following treatment with the above chemotherapeutic agents, curcumin enhanced caspase-3 activation and downregulated nuclear factor-kappa B (NF-κB) activation. Curcumin also downregulated the oxidative stress induced by certain chemotherapies. Notably, curcumin did not affect the gene expression of cell survival proteins such as B-cell lymphoma (Bcl)-2, Bcl-extra large, survivin, c-Myc and cyclin D1, which are regulated by the NF-κB transcription factor. In conclusion, curcumin has the potential to improve the effect of chemotherapeutic agents against ALL.

Curcumin improves neurofunctions of 6-OHDA-induced parkinsonian rats

Our previous study has demonstrated that curcumin (CM), a natural ingredient isolated from Zingiberaceae, exerts the effect of inhibiting hippocampal injury in 6-hydroxydopamine (6-OHDA)-induced parkinsonian rat. However, the potential effect of CM on 6-OHDA-injured substantia nigra (SN) needs to be investigated. This study aimed to further evaluate the therapeutic effectiveness of CM against damaged SN in rats. Methodologically, Parkinson's disease (PD) rat was prepared by using a surgical approach of injecting 6-hydroxydopamine (6-OHDA) into the SN. Morris water maze, open-field assays, and rotarod test were used to assess the neurobehavioral manifestations. Neurotransmitter contents in the SN were determined by using the biochemical tests. Western blotting was employed to evaluate the target protein expressions. The representative data showed that CM protected against 6-OHDA-induced neural impairments in the SN, as evidenced by improved memory abilities, elevated intercalatum levels of superoxide dismutase (SOD) and glutathione peroxidase (GSH-Px), and reduced concentration of malonaldehyde (MDA). In addition, dopamine (DA) and acetylcholine (ACh) levels were increased in the SN. Moreover, intercalatum heat shock protein 70 (HSP70) was lowered, while basic fibroblast growth factor (bFGF), nerve growth factor (NGF) and receptor tyrosine kinase A (TrkA) expressions were up-regulated, respectively. Taken together, the findings indicate that curcum in exerts neuroprotection in the SN via ameliorating neurofunctions of PD rats.

Potential effect of curcumin against neuronal death in rat prefrontal cortex through antagonizing staurosporine toxicity

Potential effect of curcumin against neuronal death in rat prefrontal cortex through antagonizing staurosporine toxicity